PMVP vs. RLMD, CTXR, RZLT, ALLK, OPTN, CLRB, CUE, ASRT, GNLX, and COYA
Should you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include Relmada Therapeutics (RLMD), Citius Pharmaceuticals (CTXR), Rezolute (RZLT), Allakos (ALLK), OptiNose (OPTN), Cellectar Biosciences (CLRB), Cue Biopharma (CUE), Assertio (ASRT), Genelux (GNLX), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical preparations" industry.
PMV Pharmaceuticals (NASDAQ:PMVP) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, community ranking, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.
PMV Pharmaceuticals received 1 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 54.84% of users gave PMV Pharmaceuticals an outperform vote while only 41.03% of users gave Relmada Therapeutics an outperform vote.
PMV Pharmaceuticals presently has a consensus price target of $5.67, suggesting a potential upside of 177.78%. Relmada Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 608.22%. Given Relmada Therapeutics' higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than PMV Pharmaceuticals.
PMV Pharmaceuticals' return on equity of -28.67% beat Relmada Therapeutics' return on equity.
90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 18.0% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.
PMV Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.
In the previous week, Relmada Therapeutics had 6 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 9 mentions for Relmada Therapeutics and 3 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 1.63 beat Relmada Therapeutics' score of 0.81 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.
Summary
PMV Pharmaceuticals beats Relmada Therapeutics on 10 of the 14 factors compared between the two stocks.
Get PMV Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PMV Pharmaceuticals Competitors List
Related Companies and Tools
